The distribution agreement enables Vygon UK and Vygon Ireland to sell Vigmed
products in the UK and Ireland on an exclusive basis.
A distribution agreement for the UK has been highly prioritized during the
recent year and by signing this agreement, Vigmed now has exclusive distribution
agreements covering all major markets in the EU.
“The agreement is a significant milestone for Vigmed as the UK is one of the
most important markets in the EU for us and we very much look forward to
introducing our unique safety products in the UK and Ireland”, says Vigmed CEO,
Henrik Olsen. “Vygon UK and Vygon Ireland are very interesting partners as they
have a vast experience both within the IV-catheter and the arterial access
“Vigmed’s products complements our customer offering very well and we have high
expectations of the partnership with Vigmed”, says Vygon UK Managing Director,
For further information contact:
Chairman of the Board Sten Dahlborg, +46 708-369 419
CEO Henrik Olsen, +46 763-497 364
This information is information that Vigmed Holding AB (publ) is obliged to make
public pursuant to the EU Market Abuse Regulation and the Securities Markets
Act. The information was submitted for publication, through the agency of the
contact persons set out above, at 1.00 pm CET on October 13, 2016.
This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
Vigmed is a Swedish medical technology company whose mission is to eliminate
needlestick injuries and the associated risk of cross infections with blood
-borne infectious diseases by offering the market unique needle-protected
products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is
traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has
approximately 5 600 shareholders. Remium Nordic AB is the Company’s Certified
Advisor.Additional information about the company can be found on Vigmed’s